Siemens

The three firms each had 510(k) clearances for multiple products from the FDA last month for marketing.

The company recorded €13.8 billion in revenues in fiscal 2017, including €4.2 billion in diagnostics, €8.2 billion in imaging, and €1.5 billion in advanced therapies. 

Siemens adds more than 80 assays and panels to its Versant kPCR molecular diagnostics system with the acquisition, which also broadens Siemens' customer base.

Microgenics, Astute Medical, and Siemens were among the firms whose tests and/or systems were cleared by the FDA for marketing last month.

Siemens noted that in closing the acquisition of Epocal, the former Alere subsidiary, it has also completed its own blood gas portfolio.

DiaSorin this week completed its acquisition of Siemens Healthineer's microtiter-based ELISA immunodiagnostic business portfolio and related assets.

The platform, comprising immunoassay and chemistry analyzers, was previously cleared by the FDA, and is now available in Europe, the US, South America, and Asia. 

The test, the fourth Zika serological assay available under EUA, qualitatively detects Zika virus IgM antibodies in human serum and plasma.

The company's new QuantStudio 5 Dx Real-Time PCR system allows users to wield multi-modal software to detect pathogens.